Evidence map›Paper›PMID 40289193›Full record

ArticleJournal of gastrointestinal cancer2025

Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database.

Richard Sassun, Annaclara Sileo, Jyi Cheng Ng, Davide Ferrari, Matthew S Block, William R G Perry, Nicholas P McKenna, Kristen K Rumer, David W Larson

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Richard Sassun *Division of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0001-7649-4703
Annaclara Sileo *Division of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Jyi Cheng NgDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Davide FerrariDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Matthew S BlockDivision of Oncology, Mayo Clinic, Rochester, MN, USA.
William R G PerryDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Nicholas P McKennaDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
Kristen K RumerDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.
David W LarsonDivision of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. Larson.David2@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnorectal melanoma (ARM) represents a problematic scenario due to a 5-year overall survival (OS) rate below 20% and its increasing incidence. Due to its comparable OS, local surgery (LS) has replaced radical surgery (RS). Adjuvant chemotherapy (Adj-CHT) and adjuvant immunotherapy (Adj-IT) are common treatments for ARM, while neoadjuvant immunotherapy (Neo-IT) has not been investigated yet. This study aimed to determine the best treatment to improve the OS.

methodsPatients with non-metastatic ARM in the National Cancer 1Database (2011-2021) who underwent surgery and received Neo-IT, Adj-IT, or Adj-CHT were included. Two cohorts were created based on the surgical approach (LS or RS). In their respective cohorts, patients receiving Neo-IT, Adj-IT, or Adj-CHT were matched 1:1:1 based on age, tumor size and location, lymphovascular invasion, and nodal disease. Kaplan-Meier analyses compared the different groups' influence on the 3-year OS.

resultsSixty patients were included in the LS cohort. Among them, there was no difference in the 3-year OS at the Kaplan-Meier analysis (Neo-IT 61%, Adj-IT 47.1%, and Adj-CHT 44%). Thirty-six patients were included in the RS cohort. Kaplan-Meier analysis for this group revealed that Neo-IT was a protective factor for 3-year OS (Neo-IT 71%, Adj-IT 11%, Adj-CHT 8%; p-value = 0.002).

conclusionNeo-IT + RS seems to improve the 3-year OS compared to the other common treatments for ARM. Neo-IT + RS can be considered a valuable treatment since prospective trials are challenging for rare diseases. When RS is not feasible, Neo-IT + LS may be beneficial as the 3-year OS reaches 61%.

Indexed as

Anus NeoplasmsMelanomaRectal NeoplasmsAdultAgedChemotherapy, AdjuvantDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesSurvival RateAnorectalChemotherapyImmunotherapyMelanomaSurgerySurvival

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.